ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 102,77
-0,22%
Dow Jones
42 801,72
0,00%
DAX
22 820,26
-0,79%
Brent Oil
70,53
1,15%
Bitcoin
83 318,82
3,39%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. AcelRX Pharmaceuticals Inc (ACRX)

  7. AcelRX Pharmaceuticals Inc (ACRX) Actualités

ACRX

AcelRX Pharmaceuticals (ACRX)

AcelRX Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ACRX
DateHeureSourceTitreSymboleSociété
25/06/202401h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
24/06/202423h24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRXAcelRX Pharmaceuticals Inc
29/04/202422h25Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ACRXAcelRX Pharmaceuticals Inc
29/04/202422h24Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ACRXAcelRX Pharmaceuticals Inc
29/04/202422h23Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ACRXAcelRX Pharmaceuticals Inc
09/01/202415h05PR Newswire (US)AcelRx Announces Rebranding With Name Change to Talphera, Inc.NASDAQ:ACRXAcelRX Pharmaceuticals Inc
12/12/202314h30PR Newswire (US)AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United StatesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
01/12/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ACRXAcelRX Pharmaceuticals Inc
22/11/202322h38Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ACRXAcelRX Pharmaceuticals Inc
22/11/202322h34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ACRXAcelRX Pharmaceuticals Inc
14/11/202312h07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACRXAcelRX Pharmaceuticals Inc
08/11/202322h05PR Newswire (US)AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ACRXAcelRX Pharmaceuticals Inc
07/11/202322h05PR Newswire (US)AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical StudyNASDAQ:ACRXAcelRX Pharmaceuticals Inc
26/10/202322h30PR Newswire (US)AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023NASDAQ:ACRXAcelRX Pharmaceuticals Inc
03/10/202314h30PR Newswire (US)AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration StudyNASDAQ:ACRXAcelRX Pharmaceuticals Inc
06/09/202314h30PR Newswire (US)AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment ConferenceNASDAQ:ACRXAcelRX Pharmaceuticals Inc
25/08/202318h45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
10/08/202322h05PR Newswire (US)AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ACRXAcelRX Pharmaceuticals Inc
09/08/202323h29Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:ACRXAcelRX Pharmaceuticals Inc
28/07/202320h07Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
27/07/202322h05PR Newswire (US)AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023NASDAQ:ACRXAcelRX Pharmaceuticals Inc
21/07/202314h00PR Newswire (US)AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
18/07/202314h00PR Newswire (US)AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesNASDAQ:ACRXAcelRX Pharmaceuticals Inc
15/06/202322h07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACRXAcelRX Pharmaceuticals Inc
10/05/202322h05PR Newswire (US)AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ACRXAcelRX Pharmaceuticals Inc
27/04/202322h05PR Newswire (US)AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023NASDAQ:ACRXAcelRX Pharmaceuticals Inc
05/04/202314h30PR Newswire (US)AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora PharmaceuticalsNASDAQ:ACRXAcelRX Pharmaceuticals Inc
30/03/202322h05PR Newswire (US)AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate UpdateNASDAQ:ACRXAcelRX Pharmaceuticals Inc
21/03/202321h05PR Newswire (US)AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023NASDAQ:ACRXAcelRX Pharmaceuticals Inc
14/03/202313h30PR Newswire (US)AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora PharmaceuticalsNASDAQ:ACRXAcelRX Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ACRX

Dernières Valeurs Consultées

BIT
F38405
Vontobel Financial Produ...
BIT
1CS
Axa
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces